SPC365

CAD in Kidney Transplant Recipients: a real-world assessment pre-ISCHEMIA-CKD

Session: Sessão Especial – Prémio Melhor Poster Electrónico
Speaker: Bruno M. Rocha

Congress: CPC 2022
Topic: K. Cardiovascular Disease In Special Populations
Theme: 30. Cardiovascular Disease in Special Populations
Subtheme: 30.9 Renal Failure and Cardiovascular Disease
Session Type: Pósters Electrónicos
FP Number: ---
Authors: Dr. Bruno Rocha; Rita Amador; Sérgio Maltês; Gonçalo jl Cunha; Catarina Mateus; Carlos Aguiar; André Weigert; Miguel Mendes
<p style="text-align:justify"><span style="font-size:11pt"><span style="font-family:Calibri,&quot;sans-serif&quot;"><strong><span style="font-size:10.0pt"><span style="font-family:&quot;Arial&quot;,&quot;sans-serif&quot;">Background: </span></span></strong><span style="font-size:10.0pt"><span style="font-family:&quot;Arial&quot;,&quot;sans-serif&quot;">The ISCHEMIA-CKD trial has shown that an initial invasive strategy, as compared to conservative treatment, did not reduce the risk of death and non-fatal myocardial infarction, nor did it improve quality-of-life in patients with advanced chronic kidney disease (CKD) and coronary artery disease (CAD) with moderate-to-severe ischemia. Similar findings were reported in patients with CKD enlisted for kidney transplantation (KT). We aimed to evaluate screening and treatment CAD strategies in patients who ultimately underwent KT at our center.</span></span></span></span></p>

<p style="text-align:justify"><span style="font-size:11pt"><span style="font-family:Calibri,&quot;sans-serif&quot;"><strong><span style="font-size:10.0pt"><span style="font-family:&quot;Arial&quot;,&quot;sans-serif&quot;">Methods: </span></span></strong><span style="font-size:10.0pt"><span style="font-family:&quot;Arial&quot;,&quot;sans-serif&quot;">This is a single-center study of consecutive patients who received a KT from 2015 to 2020. Obstructive CAD was defined whenever one of the following criteria was met: lesion with a stenosis &gt;70% (or &gt;50%, if left main disease) or CAD requiring revascularization, as per the Heart Team discussion. CAD evaluation refers to non-invasive or invasive coronary angiography and/or stress testing, irrespective of clinical scenario.</span></span></span></span></p>

<p style="text-align:justify"><span style="font-size:11pt"><span style="font-family:Calibri,&quot;sans-serif&quot;"><strong><span style="font-size:10.0pt"><span style="font-family:&quot;Arial&quot;,&quot;sans-serif&quot;">Results: </span></span></strong><span style="font-size:10.0pt"><span style="font-family:&quot;Arial&quot;,&quot;sans-serif&quot;">A total of 324 patients underwent KT [mean age 55 &plusmn; 12 years; 65.1% male; CKD most often due to hypertensive or diabetic nephropathy and polycystic kidney disease &ndash; 41.8%; median time from renal replacement therapy (RRT) to KT &ndash; 60 (40-88) months]. A flow-chart summarizing CAD</span></span> <span style="font-size:10.0pt"><span style="font-family:&quot;Arial&quot;,&quot;sans-serif&quot;">diagnosis over time is depicted in <strong><span style="color:#0070c0">figure</span></strong></span></span><strong> </strong><strong><span style="font-size:10.0pt"><span style="font-family:&quot;Arial&quot;,&quot;sans-serif&quot;"><span style="color:#0070c0">1</span></span></span></strong><span style="font-size:10.0pt"><span style="font-family:&quot;Arial&quot;,&quot;sans-serif&quot;">. Overall,</span></span> <span style="font-size:10.0pt"><span style="font-family:&quot;Arial&quot;,&quot;sans-serif&quot;">119 (36.7%)</span></span> <span style="font-size:10.0pt"><span style="font-family:&quot;Arial&quot;,&quot;sans-serif&quot;">patients had</span></span> <span style="font-size:10.0pt"><span style="font-family:&quot;Arial&quot;,&quot;sans-serif&quot;">CAD evaluation prior to KT</span></span><span style="font-size:10.0pt"><span style="font-family:&quot;Arial&quot;,&quot;sans-serif&quot;">,</span></span><span style="font-size:10.0pt"><span style="font-family:&quot;Arial&quot;,&quot;sans-serif&quot;"> of whom 21 underwent myocardial revascularization &ndash; 8, 12 and 1 patients with acute coronary syndrome (ACS), chronic coronary syndrome (CCS) and silent ischaemia, respectively. At a median time of 46 (25-66) months after KT, 36 (11.1%) more patients had CAD evaluation, of whom 8 underwent percutaneous myocardial revascularization &ndash; 6 and 2 for ACS and CCS, respectively. Those with obstructive CAD were older (64 vs 54 years-old; p&lt;0.001), with a higher burden of cardiovascular (CV) risk factors (p&lt;0.001) and more likely to have had a CV death (9.5 <em>vs.</em> 1.0%; p=0.025) or CV hospitalization (38.1 <em>vs.</em> 13.4%; p=0.007). CAD status (revascularized <em>vs.</em> non-revascularized) was not associated with improved major outcomes at follow-up. We found no strong predictors of CAD requiring revascularization post-KT, including time from RRT to KT. There were no patients with refractory angina, left main disease or reduced left ventricular ejection fraction (&lt;40%) in need of myocardial revascularization over follow-up.</span></span></span></span></p>

<p style="text-align:justify"><span style="font-size:11pt"><span style="font-family:Calibri,&quot;sans-serif&quot;"><strong><span style="font-size:10.0pt"><span style="font-family:&quot;Arial&quot;,&quot;sans-serif&quot;">Conclusions: </span></span></strong><span style="font-size:10.0pt"><span style="font-family:&quot;Arial&quot;,&quot;sans-serif&quot;">Obstructive CAD was uncommon in our cohort of patients who received a KT, most of whom with asymptomatic or mildly (monthly angina) symptomatic CCS or non-fatal ACS. These findings, together with the most recent evidence, may argue against routine CAD screening in all patients being enlisted for KT. Notwithstanding, randomized evidence is eagerly awaited to further guide treatment decisions in the post-ISCHEMIA-CKD era.</span></span></span></span></p>